Reviews in Endocrine and Metabolic Disorders

, Volume 11, Issue 4, pp 253–259 | Cite as

SERMs and SERMs with estrogen for postmenopausal osteoporosis

Article

Abstract

Bone loss with aging places postmenopausal women at a higher risk for osteoporosis and its consequences such as fractures, pain, disability, and increased morbidity and mortality. Approximately 200 million patients worldwide are affected. The Third National Health and Nutrition Examination Survey (NHANES III) estimated that up to 18% of US women aged 50 and older have osteoporosis and up to 50% have osteopenia. Greater than 2 million osteoporotic related fractures occurred in the United States with direct healthcare costs exceeding $17 billion. Hormone Replacement Therapy (HRT) was a popular option for postmenopausal women before the Women’s Health Initiative (WHI). Several agents are available in the U.S., including bisphosphonates, hormone therapy, calcitonin, parathyroid hormone and the selective estrogen receptor modulator (SERM) raloxifene. There are concerns about long term safety and compliance. Therefore, other agents are under investigation. SERMs are a diverse group of agents that bind to the estrogen receptor and each SERM appears to have a unique set of clinical responses, which are not always consistent with the typical responses seen with other SERMs. This article will discuss the SERMs approved in the United States, tamoxifene and raloxifene, and investigational SERMs. The ideal SERM would include the beneficial effects of estrogen in bone, heart and the central nervous system, with neutral or antagonistic effects in tissues where estrogen effects are undesirable(breast and endometrium). A new target in treating postmenopausal osteoporosis is the tissue estrogen complex or the pairing of a SERM with a conjugated estrogen known as a tissue selective estrogen complex (TSEC). This novel approach is currently being evaluated with bazodoxifene which could yield the beneficial effects of estrogens and SERMS, while potentially being more tolerable and safer than either therapy alone.

Keywords

Osteoporosis SERMs FRAX Tissue selective estrogen complex (TSEC) 

References

  1. 1.
    Taylor H. Approaching the ideal selective estrogen receptor modulator for prevention and treatment of postmenopausal osteoporosis. Formulary. 2010;45:52–9.Google Scholar
  2. 2.
    Looker AC, Orwell ES, Johnston Jr CC, et al. Prevalence of low femoral bone density in older U.S. adults from NHANES III. J Bone Miner Res. 1997;12:1761–8.CrossRefPubMedGoogle Scholar
  3. 3.
    Kanis JA, Oden A, Johansson H, Borgstrom F, Strom O, McCloskey E. Frax and its application in clinical practice. Bone. 2009;44:734–43.CrossRefPubMedGoogle Scholar
  4. 4.
    Siris ES, Chen YT, Abbott TA, et al. Bone mineral density thresholds for pharmacological intervention to prevent fractures. Arch Int Med. 2004;164:1108–12.CrossRefGoogle Scholar
  5. 5.
    Burge R, Dawson-Hughes B, Solomon DH, Wong JB, King A, Tosteston A. Incidence and economic burden of osteoporosis-related fractures in the United States, 2005–2025. J Bone Miner Res. 2007;22:465–75.CrossRefPubMedGoogle Scholar
  6. 6.
    Veronesi U, Boyle P, Goldhirsch A, et al. Breast cancer. Lancet. 2005;365:1451–67.CrossRefGoogle Scholar
  7. 7.
    Fisher B, Costantino JP, Wickerham DL, et al. Tamoxifen for prevention of breast cancer: report of the national surgical adjuvant breast and bowel project P-1 study. J Natl Cancer Inst. 1998;90:1371–88.CrossRefPubMedGoogle Scholar
  8. 8.
    Love RR, Cameron L, Connell BL, Leventhal H. Symptoms associated with tamoxifen treatment in postmenopausal women. Arch Intern Med. 1991;151:1842–7.CrossRefPubMedGoogle Scholar
  9. 9.
    Dignam JJ, Fisher B. Occurrence of stroke with tamoxifen in NSABP B-24. Lancet. 2000;355:848–9.CrossRefPubMedGoogle Scholar
  10. 10.
    Evista (Raloxifene HCL) (Package insert). Indianapolis, IN: Eli Lilly and Company, 2007.Google Scholar
  11. 11.
    Draper MW, Flowers DE, Huster WJ, et al. A controlled trial of raloxifene (LY 139481) HCL; impact on bone turnover and serum lipid profile in healthy Postmenopausal women. J Bone Miner Res. 1996;11:835–42.CrossRefPubMedGoogle Scholar
  12. 12.
    Delmas PD, Bjarnason NH, Mitlak BH, et al. Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women. N Engl J Med. 1997;337:1641–7.CrossRefPubMedGoogle Scholar
  13. 13.
    Johnston Jr CC, Bjarnason NH, Cohen FJ, et al. Long-term effects of raloxifene on bone mineral density, bone turnover, and serum lipids in early postmenopausal women. 3-year data from two double-blind, randomized, placebo-controlled trials. Arch Int Med. 2000;160:3444–50.CrossRefGoogle Scholar
  14. 14.
    Jolly EE, Bjarnason NH, Nevan P, et al. Prevention of osteoporosis and uterine effects in postmenopausal women taking raloxifene for 5 years. Menopause. 2003;10:337–44.CrossRefPubMedGoogle Scholar
  15. 15.
    Reid IR, Eastell R, Fogelman I, et al. A comparison of the effects of raloxifene and conjugated equine estrogen on bone and lipids in healthy postmenopausal women. Arch Intern Med. 2004;164:871–9.CrossRefPubMedGoogle Scholar
  16. 16.
    Cummings S, Eckert S, Krueger K, et al. The effect of raloxifene on risk of breast cancer in postmenopausal women. JAMA. 1999;281:2189–97.CrossRefPubMedGoogle Scholar
  17. 17.
    Ettinger B, Black DM, Mitlak BH, et al. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene; results from a 3-year randomized clinical trial. JAMA. 1999;282:637–45.CrossRefPubMedGoogle Scholar
  18. 18.
    Delmas PD, Ensrud KE, Adachi JD, et al. Efficacy of raloxifene on vertebral fracture risk reduction in postmenopausal women with osteoporosis; four year results from a randomized clinical trial. JAMA. 1999;282:637–45.CrossRefPubMedGoogle Scholar
  19. 19.
    Martino S, Cauley JA, Barrett-Connor E, et al. Continuing outcomes relevant to Evista: breast cancer incidence in postmenopausal osteoporotic women in a randomized trial of raloxifene. J Natl Cancer Inst. 2004;96:1751–61.CrossRefPubMedGoogle Scholar
  20. 20.
    Siris ES, Harris ST, Eastell R, et al. Skeletal effects of raloxifene after 8 years: results from the Continuing Outcomes Relevant to Evista (CORE) study. J Bone Miner Res. 2005;20:1514–24.CrossRefPubMedGoogle Scholar
  21. 21.
    Neven P, Quail D, Martin F, et al. Comparing raloxifene with continuous combined estrogen-progesterone therapy in postmenopausal women: review of Euralox 1. Maturitas. 2005;52:87–101.CrossRefPubMedGoogle Scholar
  22. 22.
    Barrett-Connor E, Mosca L, Collins P, et al. Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women. N Engl J Med. 2006;355:125–37.CrossRefPubMedGoogle Scholar
  23. 23.
    Shelly W, Draper M, Krishman V, et al. Selective estrogen receptor modulators: an update on recent clinical findings. Obstet Gynecol Surv. 2008;63:163–80.PubMedGoogle Scholar
  24. 24.
    Siris E, Harris S, Eastell R, et al. Effects of raloxifene on the risk of non-vertebral fractures after 8 years: results from the Continuing Outcomes Relevant to Evista (CORE) study. J Bone Miner Res. 2004;19:896.CrossRefGoogle Scholar
  25. 25.
    Cauley J, Norton L, Lippman ME, et al. Continued breast cancer risk reduction in postmenopausal women treated with raloxifene; 4-year results from the MORE trial. Breast Cancer Res Treat. 2001;65:125–34.CrossRefPubMedGoogle Scholar
  26. 26.
    Vogel VG, Costantino JP, Wickerham DL, et al. Effects of tamoxifen vs. raloxifene on the risk of developing invasive breast cancer and other disease outcomes. JAMA. 2006;295:2727–41.CrossRefPubMedGoogle Scholar
  27. 27.
    Martino S, Disch D, Dowsett SA, et al. Safety assessment of raloxifene over eight years in a clinical trial setting. Curr Med Res Opin. 2005;21:1441–52.CrossRefPubMedGoogle Scholar
  28. 28.
    Davies GC, Huster WJ, Lu Y, et al. Adverse events reported by postmenopausal women in controlled trials with raloxifene. Obstet Gynecol. 1999;93:558–65.CrossRefPubMedGoogle Scholar
  29. 29.
    Duvernoy CS, Kulkarni PM, Dowsett SA, et al. Vascular events in the Multiple Outcomes of Raloxifene Evaluation (MORE) trial: incidence, patient characteristics, and effect of raloxifene. Menopause. 2005;12:444–52.CrossRefPubMedGoogle Scholar
  30. 30.
    Grady D, Ettinger B, Moscarelli E, et al. Safety and adverse effects associated with raloxifene: multiple outcomes of raloxifene evaluation. Obstet Gynecol. 2004;104:837–44.CrossRefPubMedGoogle Scholar
  31. 31.
    Davies GC, Huster WJ, Shen W, et al. Endometrial response to raloxifene compared with placebo, cyclical hormone replacement therapy, and unopposed estrogen in postmenopausal women. Menopause. 1999;6:188–95.PubMedGoogle Scholar
  32. 32.
    Neven P, Goldstein SR, Ciaccia AV, et al. The effect of raloxifene on the incidence of ovarian cancer in postmenopausal women. Gynecol Oncol. 2002;85:388–90.CrossRefPubMedGoogle Scholar
  33. 33.
    Goldstein SR, Neven P, Zhou L, et al. Raloxifene effect on frequency of surgery for pelvic floor relaxation. Obstet Gynecol. 2001;98:91–6.CrossRefPubMedGoogle Scholar
  34. 34.
    Goldstein SR, Johnson S, Watts NB, et al. Incidence of urinary incontinence in postmenopausal women treated with raloxifene or estrogen. Menopause. 2005;12:160–4.CrossRefPubMedGoogle Scholar
  35. 35.
    Waetjen LE, Brown JS, Modelska K, et al. Effect of raloxifene on urinary incontinence; a randomized controlled trial. Obstet Gynecol. 2004;103:261–6.CrossRefPubMedGoogle Scholar
  36. 36.
    Ensrud K, Genazzani AR, Geiger MJ, et al. Effect of raloxifene on cardiovascular adverse events in postmenopausal women with osteoporosis. Am J Cardiol. 2006;97:520–7.CrossRefPubMedGoogle Scholar
  37. 37.
    Yaffe K, Krueger K, Sarkar S, et al. Cognitive function in postmenopausal women treated with raloxifene. N Eng J Med. 2001;344:1207–13.CrossRefGoogle Scholar
  38. 38.
    Yaffe K, Kreuger K, Cummings SR, et al. Effect of raloxifene on prevention of dementia and cognitive impairment in older women: Multiple Outcomes of Raloxifene Evaluation (MORE) randomized trial. Am J Psychiatry. 2005;162:683–90.CrossRefPubMedGoogle Scholar
  39. 39.
    Bolognese M, Krege J, Utian W, et al. OC45; Arzoxifene in postmenopausal women with normal or low bone mass. Bone (supplement). 2009;44:S230.Google Scholar
  40. 40.
    Ravn P, Nielsen TF, Christiansen C. What can be learned from the levormeloxifene experience? Acta Obstet Gynecol Scand. 2006;85:135–42.CrossRefPubMedGoogle Scholar
  41. 41.
    Vogelvang TE, van der Mooren MJ, et al. Emerging selective estrogen receptor modulators; special focus on effects on coronary heart disease in postmenopausal women. Drugs. 2006;66:191–221.CrossRefPubMedGoogle Scholar
  42. 42.
    Budzar A, Hayes D, El-Khoudary A, et al. Phase II randomized trial of droloxifene and tamoxifen as first-line endocrine treatment of ER/PgR-positive advanced breast cancer. Breast Cancer Res Treat. 2002;73:161–75.CrossRefGoogle Scholar
  43. 43.
    van Rietbergen E, Majumdar S, Newitt D, et al. High-resolution MRI and Micro-FE for the evaluation of changes in bone mechanical properties during longitudinal clinical trials; application to calcaneal bone in postmenopausal women after one year of idoxifene treatment. Clin Biomech (Bristol,Avon). 2002;17:81–8.CrossRefGoogle Scholar
  44. 44.
    Fleischer AC, Wheeler JE, Yeh IT, et al. Effects of clomoiphene citrate on the endometrial thickness and echogenic pattern of the endometrium. J Ultrasound Med. 1999;18:503–12.PubMedGoogle Scholar
  45. 45.
    Ariazi EA, Ariazi JL, Cordera F, et al. Estrogen receptors as therapeutic targets in breast cancer. Curr Top Med Chem. 2006;6:181–202.CrossRefPubMedGoogle Scholar
  46. 46.
    Alertazzi P, Sharma S. Urogenital effects of selective estrogen receptor modulators; a systemic review. Climacteric. 2005;8:214–20.CrossRefGoogle Scholar
  47. 47.
    Gardner M, Taylor A, Wei G, et al. Clinical pharmacology of multiple doses of lasofoxifene in postmenopausal women. J Clin Pharmacol. 2006;46:52–8.CrossRefPubMedGoogle Scholar
  48. 48.
    McClung MR, Siris E, Cummings S, et al. Prevention of bone loss in postmenopausal women treated with lasofoxifene compared with raloxifene. Menopause. 2006;13:377–86.CrossRefPubMedGoogle Scholar
  49. 49.
    Cummings S, Ensrud K, Delmas P, et al. Lasofoxifene in postmenopausal Women with osteoporosis. N Engl J Med. 2010;362:686–96.CrossRefPubMedGoogle Scholar
  50. 50.
    Komm BS, Kharode YP, Bodine PV, et al. Bazodoxifene acetate: a selective estrogen receptor modulator with improved selectivity. Endocrinology. 2005;146:3999–4008.CrossRefPubMedGoogle Scholar
  51. 51.
    Ronkin S, Northington R, Baracat E, et al. Endometrial effects of bazodoxifene acetate, a novel selective estrogen receptor modulator, in postmenopausal women. Obstet Gynecol. 2005;105:1397–404.CrossRefPubMedGoogle Scholar
  52. 52.
    Miller PD, Chines AA, Christiansen C, et al. Effects of bazodeoxifene on BMD and bone turnover in postmenopausal women: 2-year results of a randomized, double-blind, placebo-, and active-controlled study. J Bone Miner Res. 2008;23:525–35.CrossRefPubMedGoogle Scholar
  53. 53.
    Boss SM, Huster WJ, Neild JA, et al. effects of raloxifene hydrochloride on the endometrium of postmenopausal women. Am J Obstet Gynecol. 1997;177:1458–64.CrossRefPubMedGoogle Scholar
  54. 54.
    Komm B. A new approach to menopausal therapy: the tissue selective estrogen complex. Reprod Sci. 2008;15:984–92.CrossRefPubMedGoogle Scholar
  55. 55.
    Pickar J, I-Tein Y, Bachman G, et al. Endometrial effects of a tissue selective estrogen complex containing bazodoxifene/conjugated estrogens as a menopausal therapy. Fertl Steril 2009;92:1018–1024.Google Scholar
  56. 56.
    Kharode Y, Bodine PVN, Miller CP, et al. The pairing of a selective estrogen modulator, bazodoxifene, with conjugated estrogens as a new paradigmfor the treatment of postmenopausal symptoms and osteoporosis prevention. Endocrinology. 2008;149:6084–91.CrossRefPubMedGoogle Scholar
  57. 57.
    Lobo R, Pinkerton J, Gass M, et al. Evaluation of bazodoxifene/conjugated estrogens for the treatment of menopausal symptoms and effects on metabolic parameters and overall safety profile. Fertil Steril. 2009;92:1025–34.CrossRefPubMedGoogle Scholar
  58. 58.
    Archer D, Lewis V, Carr B, et al. Bazodoxifene/conjugated estrogens (BZA/CE): incidence of uterine bleeding in postmenopausal women. Fertl Steril. 2009;92:1039–44.CrossRefGoogle Scholar
  59. 59.
    Lindsay R, Gallagher J, Kagan R, et al. Efficacy of tissue-selective estrogen complex of bazodoxifene/conjugated estrogens for osteoporosis preventionin at-risk postmenopausal women. Fertl Steril. 2009;92:1045–51.CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2010

Authors and Affiliations

  1. 1.Bethesda Health ResearchBethesdaUSA
  2. 2.Johns Hopkins-Suburban HospitalBethesdaUSA

Personalised recommendations